Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.50 |
| ▸ | EED | O75530 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HLA-A | P04439 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9630130 | 0.94 | HRH1 (0.53) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL14173575 | 0.93 | HRH1 (0.55) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL5531002 | 0.92 | SSTR5 (0.52) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL4991699 | 0.90 | HRH1 (0.72) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL14173590 | 0.89 | KCNH2 (0.53) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL9699544 | 0.89 | HRH1 (0.47) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL14173581 | 0.87 | HRH1 (0.55) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL14584448 | 0.86 | HRH1 (0.54) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL4988156 | 0.85 | KCNH2 (0.57) | HRH1SSTR5KCNH2NR4A2MEN1 | |
| SCHEMBL14173568 | 0.85 | HRH1 (0.61) | HRH1SSTR5KCNH2NR4A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V (BE) (BE) | 2006-07-13 | — | — | US | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-20 | — | — | US | disclosed |
| US-6924287-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACATICA, N.V. (BE) | 2005-08-02 | — | — | US | disclosed |
| EP-1196408-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-15 | — | — | EP | disclosed |
| EP-1418175-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1196408-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885SSTR5 3981/4885KCNH2 1071/4885 |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885SSTR5 3987/4885KCNH2 1080/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | HRH1 64/4885SSTR5 3981/4885KCNH2 1071/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | HRH1 65/4885SSTR5 4137/4885KCNH2 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.